

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**21-731**

**APPROVAL LETTER**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 21-731

Atrix Laboratories, Inc.  
Attention: Cheri Jones, MS, RAC  
2579 Midpoint Drive  
Fort Collins, CO 80525-4417

Dear Ms. Jones:

Please refer to your new drug application (NDA) dated February 13, 2004, received February 18, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ELIGARD<sup>®</sup> 45mg (leuprolide acetate for injectable suspension).

We acknowledge receipt of your amendments dated: May 20, August 11, September 17, November 23 (2), December 3 and 7, 2004.

This new drug application provides for the use of ELIGARD<sup>®</sup> 45mg for the palliative treatment of advanced prostate cancer.

We completed our review of this application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) and submitted labeling (package insert submitted December 7, 2004, **and** immediate container and carton labels submitted August 11 and November 23, 2004). Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-731.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,  
and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call John C. Kim, R.Ph., J.D., Regulatory Health Project Manager, at (301) 827-3003.

Sincerely,

*{See appended electronic signature page}*

Daniel Shames, M.D.  
Director  
Division of Reproductive and Urologic Drug Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

Enclosure: Agreed-upon labeling for PI